StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Stock analysts at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ MRNS opened at $0.54 on Friday. The stock has a fifty day moving average price of $0.33 and a 200 day moving average price of $1.05. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $11.26. The company has a market cap of $29.69 million, a P/E ratio of -0.22 and a beta of 1.03.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $28,000. AQR Capital Management LLC increased its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Marinus Pharmaceuticals during the second quarter worth $64,000. World Investment Advisors LLC bought a new position in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $104,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $206,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.